In re Biolitec, Inc.
The Chapter 11 Trustee (the “Trustee”) in the chapter 11 bankruptcy proceeding of Biolitec, Inc. (the “Debtor”) has filed a motion (the “Motion”) for entry of an order (“Order”) dismissing the Debtor’s chapter 11 ease pursuant to
The Court has jurisdiction over this motion pursuant to
FACTUAL BACKGROUND
The following is an abbreviated factual and procedural history of the case, as the parties are intimately familiar with the proceedings at this point in the litigation. The Court provides only the facts relevant to this Opinion and directs the parties to earlier decisions of this Court and the district courts for further background.
1. Parties and District Court Litiga-tions
Biolitec, Inc., the Debtor, is the United States Affiliate of a multi-national group of companies in the business of manufacturing and distributing fiber optics, medical lasers, and photo-pharmaceuticals. It is a closely held corporation, 90% of which is owned by Biolitec AG, a German corporation. Neuberger owns approximately 75% of Biolitec AG, and as CEO, President, and Chairman of the Board of both the Debtor and Biolitec AG, controls the companies and their related affiliates. The Debtor’s schedules list Biolitec Holding US, Inc. as an equity holder and secured creditor of the Debtor, and CeramOptee, and Biolitec Technology Holdings, Ltd., as unsecured creditors of the Debtor.
In October 2009, AngioDynamics filed suit against the Debtor, Biolitec AG, Biomed, and Neuberger in the United States District Court for the District of Massachusetts, alleging fraudulent transfer and tortious interference with a contract (the “Massachusetts Action”). An-gioDynamics alleged that the Debtor, knowing that it was likely to incur substantial liability as a result of its obligation to defend and indemnify AngioDynamics in the patent litigations, fraudulently transferred over $18 million of assets to Biolitec AG and other affiliates between 2004 and 2009. On August 29, 2013, the district court issued a preliminary injunction that prohibited the Debtor from further transferring any assets and specifically prohibited Biolitec AG from completing a planned merger with a newly formed Austrian subsidiary.
II. Bankruptcy Proceeding and Subsequent Developments
On January 22, 2013, the Debtor filed a chapter 11 petition in this Court and immediately filed for relief from the automatic stay to allow pending litigations to continue. Due to Neuberger’s repeated defiance of court orders, the most flagrant of which was causing Biolitec AG to merge with the Austrian subsidiary in direct violation of the district court’s injunction, An-gioDynamics moved for the appointment of a chapter 11 trustee.
On August 9, 2013, the Court approved a settlement between the Trustee and’ An-gioDynamics in which substantially all of the Debtor’s assets were sold to AngioDy-namics. The settlement fixed AngioDy-namics’s allowed unsecured claim at $29 million, but provided that AngioDynamics would forego any distribution from the estate on its. $23 million Judgment Claim and would receive a distribution on the remaining $6 million Additional Damage
On August 29, 2018, the Trustee filed an adversary proceeding against Biolitec AG, Biolitec U.S., Inc., CeramOptec, Biomed, Biolitec Medical Devices, Inc., Biolitec FZ LLC, Neuberger, and several other individually named defendants, seeking, inter alia, the turnover of estate property, avoidance of unauthorized post-petition transfers of proprietary information and intellectual property, and other injunctive relief.
On March 18, 2014, the district court in the Massachusetts Action entered default judgment in favor of AngioDynamics due to the defendants’ bad faith failure to comply with discovery obligations. The court awarded AngioDynamics a $74,920,422.57 judgment against Biolitec AG, Biomed, and Neuberger, which includes an award for damages arising out of the Debtor’s fraudulent transfer of the real property that is the subject of the CeramOptec Proceeding.
III. Proposed Settlement and Structured Dismissal
On November 10, 2014, the Trustee filed a Motion to approve a second settlement between the Trustee and AngioDynamics and to dismiss, subject to a number of conditions, the Debtor’s chapter 11 bankruptcy proceeding.
• The Debtor’s chapter 11 case will be dismissed pursuant to
• With the exception of any potential interest of the estate in the Massachusetts Action, the Trustee will contribute all remaining estate assets to the Liquidating Trust. The estate will relinquish and assign any interest it has in the Massachusetts Ac
• AngioDynamics will fund the formation of the Liquidating Trust and make additional contributions for the payment of allowed administrative expense claims. AngioDynamics will also contribute any interest it might have in the real property that is the subject of the CeramOptec Proceeding to the Liquidating Trust.
• Development Specialists, Inc. (“DSI”) will be appointed as the liquidating trustee (“Liquidating Trustee”). AngioDynamics will serve as trust advisor to DSI and “provide direction or consent to all significant actions of the Liquidating Trust.”
• The Liquidating Trustee will be substituted for the Trustee in the two pending adversary proceedings and any other action commenced by the Trustee. The Liquidating Trustee will also be substituted for the Trustee to oversee the claims reconciliation and objection process. AngioD-ynamics will be joined as a party to these actions and pursue them for the benefit of the Liquidating Trust.
• All claims of the Non-Debtor Affiliates will be subordinated to all allowed claims.
• The Trustee will be released from any liability in connection with the chapter 11 case.
On November 25, 2014, the Non-Debtor Affiliates objected to the Motion and filed a Cross-Motion to convert the case to chapter 7.
DISCUSSION
I. Trustee’s Motion
The Trustee’s proposed Order seeks to approve the terms of a settlement between the Trustee and AngioDynamics pursuant to Bankruptcy
A.
The Trustee argues that
Because the Trustee’s Motion seeks to combine the proposed settlement with a dismissal of the case, its reasonableness cannot be evaluated without analyzing and considering the effect of dismissal on all parties.
B. Dismissal Pursuant to
The Motion also seeks an order dismissing the case pursuant to
The Trustee argues that dismissal is warranted under the first of the grounds listed in
Finally, the Motion requests that the Order provide, notwithstanding section 349, that all orders of this Court remain in full effect and survive the dismissal of the case, and that dismissal is subject to the Court’s approval of the settlement agreement and retention of jurisdiction over the pending adversary proceedings and all matters related to the Liquidating Trust.
C.
The Trustee argues that
It is hornbook law that§ 105(a) does not allow the bankruptcy court to override explicit mandates of other sections of the Bankruptcy Code ... We have long held that “whatever equitable powers remain in the bankruptcy courts must and can only be exercised within the confines of the Bankruptcy Code.”
Law v. Siegel, — U.S. -,
The Trustee argues that bankruptcy courts have used
Although not cited by the Trustee, the facts of In re Buffet Partners, L.P., No. 1430699,
Despite recognizing that “[n]ot much law, statutory or otherwise, exists regarding structured dismissals of this type,” the court held that
Here, the Motion, while passing the “practicality” test, must be denied because the structured dismissal seeks to alter parties’ rights without their consent and lacks many of the Code’s most important safeguards. It is well-established that
If, as the Trustee asserts, the estate lacks the funds needed to confirm or liquidate under chapter 11,
The Trustee also has not met its burden of showing that the settlement is “fair and equitable” and in the best interest of the estate and its creditors. While it may be assumed that the settlement is in the best interest of AngioDynamics, the Court must, analyze the effect of the settlement on all parties to the bankruptcy proceeding, and not simply the largest creditor, when making its reasonableness determination. See In re Buffet Partners, L.P.,
Another serious concern with the proposed settlement is the role played by AngioDynamics in the claims resolution process. Even though the Trustee concedes that this bankruptcy proceeding is essentially a two-party dispute between AngioDynamics and the Non-Debtor Affiliates, the settlement proposes that estate assets will be distributed by a Liquidating Trastee whose actions are subject to the direction or consent of AngioDynamics. The Liquidating Trustee is required to consult AngioDynamics before taking any significant action and AngioDynamics has the power to approve or disapprove the resolution of all disputed claims.
Finally, even though the settlement clearly affects parties’ rights by assigning rights and interests, forcing creditors to receive distributions through the Liquidating Trust instead of the bankruptcy process, and subordinating the claims of the Non-Debtor Affiliates, parties other than those to the settlement did not receive disclosures or the opportunity to negotiate or vote on the settlement’s
Thus, while courts have occasionally permitted structured dismissals by adopting a broad interpretation of
II. The Non-Debtor Affiliates’ Cross-Motion
In response to the Trustee’s Motion, the Non-Debtor Affiliates filed a Cross-Motion to convert the ease to chapter 7. The Non-Debtor Affiliates argue that should the Court find that cause exists under
Here, the Trustee’s Motion was filed on November 10, 2014, and scheduled to be heard on December 2, 2014. The Non-Debtor Affiliates filed their objection and Cross-Motion on November 25, 2014. The Motion was heard and the record was kept open until this date to assure sufficient time for objections to the Cross-Motion. None but those discussed here have been filed. Accordingly, for the reasons discussed, the Trustee is directed to determine whether the case should be converted to chapter 7 under
CONCLUSION
For the reasons stated above, the Trustee’s Motion is denied. The Non-Debtor Affiliates’ Cross-Motion to convert the case to chapter 7 is denied without prejudice so that the Trustee may determine whether the case should be converted to chapter 7 under
An Order in conformance with this Opinion has been entered by the Court and a copy attached hereto.
Notes
. See In re Biolitec, Inc., No. 13-11157,
. On December 4, 2014, the Trustee objected to the claims filed by the Non-Debtor Affiliates and other entities related to the Debtor. See ECF No. 592-97.
. The court did not rule on a cause of action seeking damages for costs incurred by An-gioDynamics in obtaining its own technologies to replace the infringing products acquired from Biolitec, which AngioDynamics asserts could be in excess of $8 million (the “Additional Damage Claim”).
. As a result of Neuberger’s intentional misconduct, the district court in the Massachusetts Action held the defendants in contempt of court and ordered Neuberger to appear personally to explain his actions. When Neu-berger refused to comply with the order, the court issued a warrant for his arrest and imposed fines for his failure to comply with the injunction. See AngioDynamics, Inc. v. Biolitec AG,
. See Melanie Cyganowski, Chapter 11 Trustee for Biolitec, Inc. and AngioDynamics, Inc. v. Biolitec U.S. Inc., et al., Adv. Pro. No. 13-01883, Aug. 29, 2013, ECF No. 275.
. Melanie Cyganowski, Chapter 11 Trustee for Biolitec, Inc. v. CeramOptec Industries, Inc., Adv. Pro. No. 13-02098, November 12, 2013, ECF No. 337. The adversary proceeding also seeks to avoid the Debtor's transfer of signed Andy Warhol artwork to CeramOptec for $75,000.
.See Motion for Order (i) Pursuant to Bankruptcy
. Motion, 7.
. Additionally, the Trustee argues that dismissal is warranted under § 305(a)(1). This section, traditionally employed by courts to dismiss involuntary cases, states that a court may "dismiss a case under this title, or may suspend all proceedings in a case under this title, at any time if ... the interests of creditors and the debtor would be better served by such dismissal or suspension.”
. The settlement provides that ‘‘all claims of the Non-Debtor Affiliates, whether secured or unsecured, priority and/or administrative expense claims, shall be disallowed or subordinated to all Allowed Claims, including, but not limited to, AngioDynamics’ Judgment and Claim and Additional Damage Claim, as set forth in the Dismissal Order.” Motion, Ex. A (Second Settlement Agreement by and between Biolitec, Inc. and AngioDynamics, Inc.), 6 n. 1.
. As discussed above, the settlement proposes to transfer all remaining assets of the estate to the Liquidating Trust with the exception of the estate relinquishing and assigning to An-gioDynamics any interest it might have in any potential recovery obtained by AngioDynam-ics from the Non-Debtor Affiliates and related entities in the Massachusetts Action or any other action commenced by AngioDynamics to collect on its Judgment Claim (although AngioDynamics agreed to contribute a portion of any recovery obtained on its Judgment Claim to the Liquidating Trust).
. There is also a legitimate question as to whether the Court would be able to exercise jurisdiction over the pending adversary proceedings, which are "core” to the Debtor’s bankruptcy, following a dismissal of the case. See Henson v. NovaStar Mortg., Inc. (In re Henson), No. 06-20122,
. See Motion, Ex. B (Biolitec, Inc. Liquidating Trust Agreement), 11 at ¶ 5.1.